Showing 1 - 10 of 77
Persistent link: https://www.econbiz.de/10014420073
Persistent link: https://www.econbiz.de/10014268367
Persistent link: https://www.econbiz.de/10000102644
Persistent link: https://www.econbiz.de/10012350752
Persistent link: https://www.econbiz.de/10000341678
Persistent link: https://www.econbiz.de/10004656678
Persistent link: https://www.econbiz.de/10012875850
The results suggest that trastuzumab as adjuvant therapy for early breast cancer may be cost effective when given over either 52 or 9 weeks at current acquisition costs in Australia. However, the overall budget impact of the 52-week course is significant, and the 9-week course appears...
Persistent link: https://www.econbiz.de/10011001785